NetworkNewsBreaks – Earth Science Tech, Inc. (ET
Post# of 333
(Total Views: 214)
Posted On: 02/28/2018 4:35:19 PM
NetworkNewsBreaks – Earth Science Tech, Inc. (ETST) Finalizes Plans for Human Trial of CBD-based Formula Targeting Opioid Addiction
Earth Science Tech, Inc. (OTC: ETST) this morning reported that it has finalized preparations for its nine-month human trial to evaluate the effectiveness of a blend of broad-spectrum cannabinoid industrial hemp oil and essential mineral element. The trial seeks to develop a CBD formulation for the treatment of opioid addicts, relieving withdrawal symptoms, and averting fatal overdoses. ETST aims to increase the potency of its formulation by combining its full-spectrum cannabinoids industrial hemp oil with essential minerals. The trial is scheduled to be completed in 2019 and it will be supervised by ETST chief learning officer Gabriel Aviles and CEO Dr. Michel Aube. Per the update, ETST is prepared to manufacture and introduce new products in the market to combat the current scourge of opioid deaths in America if the formulation proves successful. ETST is currently collaborating with CGMP laboratory to mix the anti-opioid formula for the human trials, and it is in talk with rehabilitation centers that are interested in participating in the project.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Earth Science Tech, Inc. (OTC: ETST) this morning reported that it has finalized preparations for its nine-month human trial to evaluate the effectiveness of a blend of broad-spectrum cannabinoid industrial hemp oil and essential mineral element. The trial seeks to develop a CBD formulation for the treatment of opioid addicts, relieving withdrawal symptoms, and averting fatal overdoses. ETST aims to increase the potency of its formulation by combining its full-spectrum cannabinoids industrial hemp oil with essential minerals. The trial is scheduled to be completed in 2019 and it will be supervised by ETST chief learning officer Gabriel Aviles and CEO Dr. Michel Aube. Per the update, ETST is prepared to manufacture and introduce new products in the market to combat the current scourge of opioid deaths in America if the formulation proves successful. ETST is currently collaborating with CGMP laboratory to mix the anti-opioid formula for the human trials, and it is in talk with rehabilitation centers that are interested in participating in the project.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)